Literature DB >> 17097597

Best practices for preventing musculoskeletal disorders in masonry: stakeholder perspectives.

Pamela Entzel1, Jim Albers, Laura Welch.   

Abstract

Brick masons and mason tenders report a high prevalence of work-related musculoskeletal disorders (WMSDs), many of which can be prevented with changes in materials, work equipment or work practices. To explore the use of "best practices" in the masonry industry, NIOSH organized a 2-day meeting of masonry stakeholders. Attendees included 30 industry representatives, 5 health and safety researchers, 4 health/safety specialists, 2 ergonomic consultants, and 2 representatives of state workers' compensation programs. Small groups discussed ergonomic interventions currently utilized in the masonry industry, including factors affecting intervention implementation and ways to promote diffusion of interventions. Meeting participants also identified various barriers to intervention implementation, including business considerations, quality concerns, design issues, supply problems, jobsite conditions and management practices that can slow or limit intervention diffusion. To be successful, future diffusion efforts must not only raise awareness of available solutions but also address these practical concerns.

Entities:  

Mesh:

Year:  2006        PMID: 17097597     DOI: 10.1016/j.apergo.2006.08.004

Source DB:  PubMed          Journal:  Appl Ergon        ISSN: 0003-6870            Impact factor:   3.661


  2 in total

1.  Observed use of voluntary controls to reduce physical exposures among sheet metal workers of the mechanical trade.

Authors:  Ann Marie Dale; Kim Miller; Bethany T Gardner; Ching-Ting Hwang; Bradley Evanoff; Laura Welch
Journal:  Appl Ergon       Date:  2015-07-15       Impact factor: 3.661

2.  Safety voice for ergonomics (SAVE) project: protocol for a workplace cluster-randomized controlled trial to reduce musculoskeletal disorders in masonry apprentices.

Authors:  Laurel D Kincl; Dan Anton; Jennifer A Hess; Douglas L Weeks
Journal:  BMC Public Health       Date:  2016-04-27       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.